-
Medicines Company Rallies On Positive LDL Cholesterol Study Results
Monday, May 20, 2019 - 9:42am | 442Small-cap biotech The Medicines Company (NASDAQ: MDCO) announced long-term results over the weekend from a midstage study of its lead product candidate Inclisiran, sending its shares higher. What Happened Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study...
-
Amgen Stock Falls After 'Boring' Q3 Beat
Thursday, October 26, 2017 - 10:49am | 449Reviewing Amgen, Inc. (NASDAQ: AMGN)'s third-quarter results, Cowen said the results were boring but very safe. The firm maintains its Buy rating and $209 price target for the shares of the company. At the time of writing, shares of Amgen were trading down 1.67 percent at $174.54. Analysts...
-
'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts
Wednesday, July 26, 2017 - 4:33pm | 622Amgen, Inc. (NASDAQ: AMGN) Tuesday earnings report was of "poor-quality" and the company doesn't have any near-term catalysts to support the stock, analysts at BMO Capital Markets said. Analyst M. Ian Somaiya downgraded Amgen's stock rating from Outperform to Market Perform...
-
Amgen's Repatha Results Not Good Enough For The Street
Friday, March 17, 2017 - 9:42am | 432Shares of Amgen, Inc. (NASDAQ: AMGN) fell 7 percent after the biotechnology company released data from its therapy called Repatha, which is used to lower the risk of heart attacks, strokes and heart problems. Amgen reported Repatha reduces the risk of heart attacks, stokes and other heart-related...
-
Esperion Surge May Be Fueled By Repatha Short Squeeze
Tuesday, February 7, 2017 - 2:28pm | 324Esperion Therapeutics Inc (NASDAQ: ESPR) has maintained its upward momentum on Tuesday, surging higher by another 13.2 percent. While the massive 80 percent runup since January 30 was triggered by positive fundamental news, a major short squeeze may be fueling the stock's enduring momentum. On...
-
Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April
Tuesday, January 10, 2017 - 10:06am | 357After the close on Monday, Amgen, Inc. (NASDAQ: AMGN) announced that the U.S. District Court of Delaware had denied the motion by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to stay the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of...
-
Regeneron Falls As Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents
Friday, January 6, 2017 - 9:54am | 279Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (ADR) (NYSE: SNY) could come under pressure after a U.S. district court ruled in favor of Amgen, Inc. (NASDAQ: AMGN) in a patent infringement lawsuit. Lawsuit The U.S. District Court in Delaware's permanent injunction...
-
Barclays Says Acceleration For Amgen Could Be A Challenge
Thursday, July 28, 2016 - 11:18am | 432Amgen, Inc. (NASDAQ: AMGN) reported robust 2Q results on both the top and bottom lines, modestly beating expectations. Barclays’ Geoff Meacham maintained an Equal-Weight rating on the company, with a price target of $185. Further Acceleration Could Be Challenging “While we have fairly...
-
Amgen's Near-Term Catalyst Is Ph3 IVUS According To Goldman Sachs
Wednesday, June 15, 2016 - 8:17am | 289Following in the delay in the release of data by Amgen, Inc. (NASDAQ: AMGN) for its ongoing Repatha Phase 3 trials, Goldman Sachs’ Terence Flynn now believes that the Phase 3 IVUS data could be a more important near-term catalyst for the stock. Flynn maintains a Buy rating on the company,...
-
Jury In Repatha Patent Case Ruled In Favor Of Amgen, Against Regeneron And Sanofi
Wednesday, March 16, 2016 - 3:05pm | 324Amgen, Inc. (NASDAQ: AMGN) has won a patent suit against Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (ADR) (NYSE: SNY) over its cholesterol-lowering drug Repatha. Amgen said a Delaware jury ruled in favor of the company on the validity of two Amgen patents that describe...